These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 37405409)

  • 21. Immunopathology of COVID-19 and its implications in the development of rhino-orbital-cerebral mucormycosis: a major review.
    Dave TV; Nair AG; Joseph J; Freitag SK
    Orbit; 2022 Dec; 41(6):670-679. PubMed ID: 35856238
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mucormycosis in Africa: Epidemiology, diagnosis and treatment outcomes.
    Osaigbovo II; Ekeng BE; Davies AA; Oladele RO
    Mycoses; 2023 Jul; 66(7):555-562. PubMed ID: 36856432
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Rhino-orbito-cerebral mucormycosis: patient characteristics in pre-COVID-19 and COVID-19 period.
    Cherian LM; Varghese L; Rupa V; Bright RR; Abraham L; Panicker R; R N; Peter J; Nayak A; Shyam A; Varghese GM; Manesh A; Karuppusami R; George K; George T; Lenin A; Hansdak SG; I R; Michael JS; Ninan M; Thomas M; Kurian R; Mammen S; Kurien R
    Rhinology; 2022 Dec; 60(6):427-434. PubMed ID: 36150158
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Battling the emerging epidemic of rhino-orbital-cerebral mucormycosis (ROCM) in COVID-19 pandemic: an interventional study.
    Gandhi A; Narula A; Chandra S; Agarwal D; Mehta A; Nayak S; Arora S; Capoor MR
    Int Ophthalmol; 2023 May; 43(5):1571-1580. PubMed ID: 36273362
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sinonasal and Orbital Imaging Findings in COVID-Associated Rhino-Orbito-Cerebral Mucormycosis During the Second Wave of COVID-19: A Retrospective Cohort Study in a Tertiary Hospital in Central India.
    B H S; Kumbhalkar S; Selvi K; G D; Bidkar V; Dabhekar S; Prathipati K; Sawal A
    Cureus; 2023 Jul; 15(7):e42674. PubMed ID: 37649953
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Histomorphological features of mucormycosis with rise and fall of COVID-19 pandemic.
    Ganesan N; Sivanandam S
    Pathol Res Pract; 2022 Aug; 236():153981. PubMed ID: 35749915
    [TBL] [Abstract][Full Text] [Related]  

  • 27. ECMM/ISHAM recommendations for clinical management of COVID-19 associated mucormycosis in low- and middle-income countries.
    Rudramurthy SM; Hoenigl M; Meis JF; Cornely OA; Muthu V; Gangneux JP; Perfect J; Chakrabarti A;
    Mycoses; 2021 Sep; 64(9):1028-1037. PubMed ID: 34133816
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Uncontrolled diabetes mellitus exacerbated by COVID-19-induced inflammation is the risk factor for COVID-19-associated rhino-orbito-cerebral mucormycosis: A matched pair case-control study.
    Karat S; Lobo AC; Satish D; Devaraj R; Manjooran RR; Nithyanandam S
    Indian J Ophthalmol; 2022 Aug; 70(8):3096-3101. PubMed ID: 35918980
    [TBL] [Abstract][Full Text] [Related]  

  • 29. COVID-19-associated mucormycosis in India: Why such an outbreak?
    Pasquier G
    J Mycol Med; 2023 Aug; 33(3):101393. PubMed ID: 37182234
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A Comparison Between Potassium Hydroxide (KOH) Microscopy and Culture for the Detection of Post-COVID-19 Rhino-Orbital-Cerebral Mucormycosis.
    Hasan S; Gupta P; Shukla D; Banerjee G
    Cureus; 2023 Oct; 15(10):e47707. PubMed ID: 38022015
    [TBL] [Abstract][Full Text] [Related]  

  • 31. COVID-19-associated rhino-orbital-cerebral mucormycosis: A systematic review, meta-analysis, and meta-regression analysis.
    Bhattacharyya A; Sarma P; Kaur H; Kumar S; Bhattacharyya J; Prajapat M; Prakash A; Sharma S; Reddy DH; Thota P; Bansal S; Gautam BS; Medhi B
    Indian J Pharmacol; 2021; 53(6):499-510. PubMed ID: 34975140
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical Phenotypes of COVID-19 Associated Mucormycosis (CAM): A Comprehensive Review.
    Almyroudi MP; Akinosoglou K; Rello J; Blot S; Dimopoulos G
    Diagnostics (Basel); 2022 Dec; 12(12):. PubMed ID: 36553099
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Whole genome analysis of
    Michael JS; Venkatesan M; Ninan MM; Solaimalai D; Sumanth LJ; Varghese L; Kurien R; Varghese RP; C GPD
    Front Cell Infect Microbiol; 2023; 13():1251456. PubMed ID: 38029246
    [TBL] [Abstract][Full Text] [Related]  

  • 34. As the virus sowed, the fungus reaped! A comparative analysis of the clinico-epidemiological characteristics of rhino-orbital mucormycosis before and during COVID-19 pandemic.
    Muraleedharan M; Panda NK; Angrish P; Arora K; Patro SK; Bansal S; Chakrabarti A; Rudramurthy SM; Bakshi J; Mohindra S; Gupta R; Virk RS; Verma RK; Ramavat AS; Nayak G
    Mycoses; 2022 May; 65(5):567-576. PubMed ID: 35289000
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mucormycosis in 2023: an update on pathogenesis and management.
    Alqarihi A; Kontoyiannis DP; Ibrahim AS
    Front Cell Infect Microbiol; 2023; 13():1254919. PubMed ID: 37808914
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Post-Covid Cerebral Mucormycosis, Varied Presentations and Surgical Strategies of a Newer Epidemic: An Institutional Experience.
    Vijayasekhar MV; Nagappa V; Swaroop KH; Mithun G; Achuith E; Varaprasad KS
    Neurol India; 2022; 70(3):1052-1056. PubMed ID: 35864638
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Risks of mucormycosis in the current Covid-19 pandemic: a clinical challenge in both immunocompromised and immunocompetent patients.
    Monika P; Chandraprabha MN
    Mol Biol Rep; 2022 Jun; 49(6):4977-4988. PubMed ID: 35107737
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Epidemiology, clinical presentation and management of COVID-19 associated mucormycosis: A single centre experience from Pune, Western India.
    Dravid A; Kashiva R; Khan Z; Bande B; Memon D; Kodre A; Mane M; Pawar V; Patil D; Kalyani S; Raut P; Bapte M; Saldanha C; Chandak D; Patil T; Reddy S; Bhayani K; Suresh L; Dillibabu V; Srivastava S; Khandelwal S; More S; Shakeel A; Pawar M; Nande P; Harshe A; Kadam S; Hallikar S; Kamal N; Andrabi D; Bodhale S; Raut A; Chandrashekhar S; Raman C; Mahajan U; Joshi G; Mane D
    Mycoses; 2022 May; 65(5):526-540. PubMed ID: 35212032
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Multicenter Epidemiologic Study of Coronavirus Disease-Associated Mucormycosis, India.
    Patel A; Agarwal R; Rudramurthy SM; Shevkani M; Xess I; Sharma R; Savio J; Sethuraman N; Madan S; Shastri P; Thangaraju D; Marak R; Tadepalli K; Savaj P; Sunavala A; Gupta N; Singhal T; Muthu V; Chakrabarti A;
    Emerg Infect Dis; 2021 Sep; 27(9):2349-2359. PubMed ID: 34087089
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Spectrum of intracranial complications of rhino-orbito-cerebral mucormycosis - resurgence in the era of COVID-19 pandemic: a pictorial essay.
    Kaushik KS; Ananthasivan R; Acharya UV; Rawat S; Patil UD; Shankar B; Jose A
    Emerg Radiol; 2021 Dec; 28(6):1097-1106. PubMed ID: 34605991
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.